Print

News

  • WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)

    Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market. Read More
  • IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)

    IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019) Read More
  • The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)

    The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019) Read More
  • Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discovery

    October 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Print

Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.

Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA). 

Annual Conference - Warsaw 2019

Annual Conference - Budapest 2018

Annual Conference - Lisboa 2017

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

c/o Interexperts SA
Rue des Pierres-du-Niton 17
1207 Geneva, Switzerland

Telephone: +32 (0)2 5346607
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or 
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site